
Bemesetron
CAS No. 40796-97-2
Bemesetron( MDL 72222 | 3-TROPANYL-3,5-DICHLOROBENZOATE | TROPANYL 3,5-DICHLOROBENZOATE )
Catalog No. M26626 CAS No. 40796-97-2
Bemesetron is a selective antagonist of 5-HT3 (IC50 = 0.33 nM) with neuroprotective effects.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
10MG | 45 | In Stock |
![]() ![]() |
25MG | 58 | In Stock |
![]() ![]() |
50MG | 77 | In Stock |
![]() ![]() |
100MG | Get Quote | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameBemesetron
-
NoteResearch use only, not for human use.
-
Brief DescriptionBemesetron is a selective antagonist of 5-HT3 (IC50 = 0.33 nM) with neuroprotective effects.
-
DescriptionBemesetron is a selective antagonist of 5-HT3 (IC50 = 0.33 nM) with neuroprotective effects.(In Vitro):In primary cortical neuronal cells, Bemesetron (1 μM) significantly blocks the H2O2-induced increase of caspase-3 immunoreactivity. Bemesetron (0.01, 0.1 and 1 μM) and Y25130 (0.05, 0.5 and 5 μM) concentration-dependently reduce the H2O2-induced decrease showing inhibition of 74.9 and 79.0% with 1 μM and 5 μM, respectively.(In Vivo):In male adult albino mice, Bemesetron (1 mg/kg; i.p.) causes a significant reduction of catalepsy, while Bemesetron (10 mg/kg; i.p.) significantly potentiates the phenomenon. The maximum inhibition of catalepsy (about 75%) occurs at 120 min, and the maximum potentiation (about 4.5-times the control value) occurs at 60 min after Haloperidol.
-
In VitroBlockade of 5-HT3 receptor with Bemesetron (MDL7222) reduces hydrogen peroxide-induced neurotoxicity in cultured rat cortical cells. Bemesetron (0.01, 0.1 and 1 μM, 15 hours) and Y25130 (0.05, 0.5 and 5 μM) concentration-dependently reduce the H2O2-induced decrease of MTT reduction showing 74.9±2.4 and 79.0 ±2.5% with 1 μM and 5 μM, respectively, which are maximal effects. Pretreatment (20 minutes) with Bemesetron (1 μM), Y25130 (5 μM) or MK-801 (10 μM) significantly, but not completely, inhibits the H2O2-induced elevation of [Ca2+]c. Bemesetron (1 μM, 15 hours) significantly blocks the H2O2-induced increase of caspase-3 immunoreactivity.Cell Viability Assay Cell Line:Primary cortical neuronal cells Concentration:0.01-1 μM Incubation Time:20 minutes (pretreatment); 15 hours (post-incubation)Result:Concentration-dependently reduced the H2O2-induced decrease of MTT reduction showing 74.9±2.4% with 1 μM, which was maximal effect.Western Blot Analysis Cell Line:Primary cortical neuronal cells Concentration:1 μM Incubation Time:15 hours Result:Blocked significantly the H2O2-induced increase of caspase-3 immunoreactivity.
-
In VivoBemesetron (0.1, 1 and 10 mg/kg; i.p.) is used in male adult albino mice. The lowest dose do not cause any significant change in catalepsy. However, Bemesetron (1 mg/kg) causes a significant reduction of catalepsy (from 90 min after Haloperidol), while 10 mg/kg significantly potentiates the phenomenon (from 60 min after Haloperidol). The maximum inhibition of catalepsy (about 75%) occurs at 120 min, and the maximum potentiation (about 4.5-times the control value) occurs at 60 min after Haloperidol. Animal Model:Male adult albino mice, weighing 26-36 g Dosage:0.1-10 mg/kg Administration:Intraperitoneally injected, 20 min (pretreatment) +180 min (treatment)Result:Reduced catalepsy significantly at a dose of 1 mg/kg, whilst 10 mg/kg potentiated the phenomenon and 0.1 mg/kg was found to be without effect.
-
SynonymsMDL 72222 | 3-TROPANYL-3,5-DICHLOROBENZOATE | TROPANYL 3,5-DICHLOROBENZOATE
-
PathwayEndocrinology/Hormones
-
Target5-HT Receptor
-
RecptorNLRP3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number40796-97-2
-
Formula Weight314.21
-
Molecular FormulaC15H17Cl2NO2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 2 mg/mL (6.37 mM)
-
SMILESCN1[C@H]2CC[C@@H]1C[C@@H](C2)OC(=O)c1cc(Cl)cc(Cl)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ruan S, et al. Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3. Int Immunopharmacol. 2021 Nov;100:108126.
molnova catalog



related products
-
Trimipramine maleate
Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.
-
KW-2478
KW-2478 is a non-ansamycin HSP90 inhibitor with IC50 of 3.8 nM.
-
Triflupromazine hydr...
Triflupromazine hydrochloride is an antipsychotic medication, which are Dopamine D1/D2 receptor antagonists.